<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02331823</url>
  </required_header>
  <id_info>
    <org_study_id>2013ZX10003009</org_study_id>
    <nct_id>NCT02331823</nct_id>
  </id_info>
  <brief_title>Research on New Regimens for Retreatment Pulmonary Tuberculosis</brief_title>
  <official_title>New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, prospective study is performed to investigate the efficacy of new short-course
      regimen for retreatment pulmonary tuberculosis patients.

      To obtain optimized short-course regimen, decrease treatment cost and improve success rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      China is the country with the second highest Tuberculosis (TB) burden in the world. Most of
      the retreatment TB patients may develop multi-drug resistant. The resistant rate of any of
      the anti-TB drug is 35.9%, and the multi-drug resistant rate is 15.4%. Retreatment TB becomes
      one of the factors which inhibit the decrease of morbidity and mortality of TB. It is also a
      tuff work in TB control. At present the standardized regimen for retreatment TB is
      2SHREZ/6HRE or 3HREZ/6HRE. The drugs in the regimen are all first-line anti-TB drugs which
      are unsuitable for the high drug resistance prevalence, because the cure rate of this regimen
      is low and the adverse reaction is severe.

      Our study is a national multi-center, prospective trail to investigate the efficacy of a new
      super-short regimen for retreatment TB patients. The new regimen consists of 5 drugs lasting
      5 months. The cure rate and success rate of the new regimen is compared with standardized
      regimen usually 8-9 months in order to obtain the optimized regimen.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>success rate</measure>
    <time_frame>for arm A,the point is 5 month after treatment. For arm B,the time point is at the end of the 8 or 9 month's treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse reaction rate</measure>
    <time_frame>for arm A,the point is 5 month after treatment. For arm B,the time point is at the end of the 8 or 9 month's treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">864</enrollment>
  <condition>Reinfection Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>arm A: super-short retreatment regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A regimen of 5 drugs is to be administered. Isoniazid Aminosalicylate Tablets,0.3g tid po for 5 mon moxifloxacin tab, 0.4g qd po for 5 mon rifabutin capsule,0.3g qd po for 5 mon ethambutol tab, 0.75g qd po for 5 mon pyrazinamide tab, 0.5g tid po for 5 mon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm B:standardized retreatment regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8-9 months of standardized regimen is to be administered. regimen 1.2SHREZ/6HRE streptomycin injectable,0.75g qd intramuscular for 2 mon isoniazid tab,0.3g qd po for 8 mon rifampicin capsule,0.45-0.6g po for 8 mon ethambutol tab, 0.75g qd po for 8 mon pyrazinamide tab, 0.5g tid po for 2 mon or regimen 2.3HREZ/6HRE isoniazid tab,0.3g qd po for 9 mon rifampicin capsule,0.45-0.6g po for 9 mon ethambutol tab, 0.75g qd po for 9 mon pyrazinamide tab, 0.5g tid po for 3 mon</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid Aminosalicylate Tablets</intervention_name>
    <description>a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.</description>
    <arm_group_label>arm A: super-short retreatment regimen</arm_group_label>
    <other_name>ethambutol tablets</other_name>
    <other_name>pyrazinamide tablets</other_name>
    <other_name>rifabutin capsules</other_name>
    <other_name>moxifloxacin tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Streptomycin injectable</intervention_name>
    <description>standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.</description>
    <arm_group_label>arm B:standardized retreatment regimen</arm_group_label>
    <other_name>isoniazid tablets</other_name>
    <other_name>ethambutol tablets</other_name>
    <other_name>rifampicin capsules</other_name>
    <other_name>pyrazinamide tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sputum confirmed diagnosis of retreatment pulmonary tuberculosis

          -  Must be able to swallow tablets

          -  Must be able to sign written informed consent form

        Exclusion Criteria:

          -  Extra-pulmonary tuberculosis

          -  Diabetes

          -  Allergy to any of the medications in the regimen or pregnancy

          -  Liver disease

          -  Renal disease

          -  Metabolic disease

          -  Immune system disease

          -  Hematological disease

          -  Nervous system and mental disease

          -  Endocrine disease

          -  Malignant disease

          -  Receiving immunosuppressive therapy

          -  HIV/AIDS

          -  Alcohol addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heping Xiao, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital,China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qing Zhang, M.D</last_name>
    <phone>8621-65115006</phone>
    <phone_ext>2002</phone_ext>
    <email>zhqi709851@sohu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Sha, M.D</last_name>
    <phone>8621-65115006</phone>
    <phone_ext>2017</phone_ext>
    <email>shfksw@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Zhang, M.D</last_name>
      <phone>8621-65115006</phone>
      <phone_ext>2002</phone_ext>
      <email>zhqi709851@sohu.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Sha, M.D</last_name>
      <phone>8621-65115006</phone>
      <phone_ext>2017</phone_ext>
      <email>shfksw@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qing Zhang, M.d</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2014</study_first_submitted>
  <study_first_submitted_qc>January 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>January 2, 2015</last_update_submitted>
  <last_update_submitted_qc>January 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Qing Zhang</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
    <mesh_term>Streptomycin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

